Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta

Journal of Children's Orthopaedics

Volumn 5, Issue 2, 2011, Pages 121-125

  de Graaff, F ^a   Verra, W ^a   Pruijs, J E H ^a   Sakkers, R J B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bisphosphonates; Children; Operative intervention; Osteogenesis imperfecta; Outpatient department

Indexed keywords

EID: 79952703115     PISSN: 18632521     EISSN: 18632548     Source Type: Journal    
DOI: 10.1007/s11832-010-0305-3     Document Type: Article

References (15)

1. Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16: 101-116.
2. Prockop DJ, Kivirikko KI (1984) Heritable diseases of collagen. N Engl J Med 311: 376.
3. Engelbert RH, Pruijs HE, Beemer FA, Helders PJ (1998) Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil 79: 1590.
4. Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363: 1377.
5. Engelbert RH, Beemer FA, van der Graaf Y, Helders PJ (1999) Osteogenesis imperfecta in childhood: impairment and disability-a follow-up study. Arch Phys Med Rehabil 80: 896.
6. Lindsay R (2002) Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest 110: 9.
7. Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363(9419): 1427-1431.
8. Plotkin H, Rauch F, Bishop NJ et al (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 1846.
9. DiMeglio LA, Ford L, McClintock C, Peacock M (2004) Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 35: 1038.
10. Rauch F, Plotkin H, Zeitlin L, Glorieux FH (2003) Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18: 610-614.
11. Kok DH, Sakkers RJ, Janse AJ, Pruijs HE, Verbout AJ, Castelein RM, Engelbert RH (2007) Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controlled trial. Eur J Pediatr 166: 1155.
12. Munns CF, Rauch F, Travers R, Glorieux FH (2005) Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical, histomorphometric outcome. J Bone Miner Res 20: 1235.
13. Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M et al (2003) Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 111: 601-603.
14. Glorieux FH (2001) The use of bisphosphonates in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 14: 1491-1495.
15. Arikoski P, Silverwood B, Tillmann V, Bishop NJ (2004) Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 34(3): 539-546.